KLK3 and prostate carcinoma: One such trial [40] was based on PSA measurement over one year in a group of patients, all of whom had established prostate cancer, and suggested that over 60% benefited from the reduced rate of acceleration of PSA or, in about 20% of the cases, an actual reduction in PSA.